Prognostic test for lung cancer on horizon
This article was originally published in Clinica
The discovery of two gene expression profiles could pave the way to prognostic tests for lung cancer. The researchers, from the Mayo Clinic in Rochester, Minnesota, believe that the tests will lead to "better personalised treatment options" for sufferers of non-small cell lung cancer (NSCLC).
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.